Pacific Biosciences Of Stock Investor Sentiment
| PACB Stock | USD 1.64 0.04 2.50% |
About 58% of Pacific Biosciences' investor base is looking to short. The analysis of overall sentiment of trading Pacific Biosciences of stock suggests that many investors are alarmed at this time. The current market sentiment, together with Pacific Biosciences' historical and current headlines, can help investors time the market. In addition, many technical investors use Pacific Biosciences stock news signals to limit their universe of possible portfolio assets.
Pacific |
Pacific Biosciences Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Pacific Biosciences can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Far too much social signal, news, headlines, and media speculation about Pacific Biosciences that are available to investors today. That information is available publicly through Pacific media outlets and privately through word of mouth or via Pacific internal channels. However, regardless of the origin, that massive amount of Pacific data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Pacific Biosciences news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Pacific Biosciences relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Pacific Biosciences' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Pacific Biosciences alpha.
Pacific Biosciences Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | PacBio Announces SPRQ Chemistry for Revio Sequencing Systems, a Major Advance Reducing the Cost of a HiFi Human Genome to less than 500 | 10/29/2024 |
2 | Pacific Biosciences Q3 Earnings Taking a Look at Key Metrics Versus Estimates | 11/08/2024 |
3 | Pacific Biosciences of California, Inc. Among the Best Genomics Stocks to Buy Right Now | 11/20/2024 |
4 | Pacific Biosciences Appoints CEO as Interim CFO - TipRanks | 12/06/2024 |
5 | Growth Trends in the Whole Genome and Exome Sequencing Market, 2029 An Assessment of Demand Drivers and Country-Level Business Opportunities by Product, Applica... | 12/17/2024 |
6 | Disposition of 25000 shares by Mohr Marshall of Pacific Biosciences at 4.45 subject to Rule 16b-3 | 12/27/2024 |
7 | PacBio to Present at 43rd Annual J.P. Morgan Healthcare Conference | 01/02/2025 |
8 | PacBio Announces Shipment of Vega Systems to Berry Genomics to Support its Clinical Assay Development for Asian Markets | 01/08/2025 |
9 | Disposition of 34405 shares by Van Oene Mark of Pacific Biosciences at 2.034 subject to Rule 16b-3 | 01/10/2025 |
10 | PacBio and Radboud UMC Announce Remarkable Study Results Using HiFi Long Read Sequencing to ... | 01/14/2025 |
11 | PACB Stock Falls on Preliminary Q4 Sales Miss, 7 Vega Systems Shipped | 01/15/2025 |
Complementary Tools for Pacific Stock analysis
When running Pacific Biosciences' price analysis, check to measure Pacific Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pacific Biosciences is operating at the current time. Most of Pacific Biosciences' value examination focuses on studying past and present price action to predict the probability of Pacific Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pacific Biosciences' price. Additionally, you may evaluate how the addition of Pacific Biosciences to your portfolios can decrease your overall portfolio volatility.
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories |